Patent ID: 9597341
Date: 2017-03-21
CPC Classifications: A61K,A61N,A61P,C07F

Claim:
1. A method of treating cancer in a subject in need thereof, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the aesophagus and liver, lymphoblastic leukaemias, non-Hodgkin lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, and small-cell lung cancer, comprising administration of an effective amount of a phosphate compound of formula (I): wherein: X and Y represent a carbon atom or a nitrogen atom, wherein X and Y may not simultaneously represent two carbons atoms or two nitrogen atoms; A T represents a hydrogen atom, a linear or branched (C R R R R R R R it being understood that: “aryl” means a phenyl, naphthyl, biphenyl or indenyl group, “heteroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 4 hetero atoms selected from oxygen, sulphur and nitrogen (including quaternary nitrogens), “cycloalkyl” means any mono- or bi-cyclic, non-aromatic, carbocyclic group containing from 3 to 10 ring members, “heterocycloalkyl” means any mono- or bi-cyclic, non-aromatic, condensed or spiro group composed of 3 to 10 ring members and containing from 1 to 3 hetero atoms selected from oxygen, sulphur, SO, SO wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the groups alkyl, alkenyl, alkynyl and alkoxy may be optionally substituted by from I to 3 groups selected from optionally substituted, linear or branched (C 1 -C 6 )alkyl, (C 3 -C 6 )spiro, linear or branched, optionally substituted (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-S—, hydroxy, oxo (or N-oxide where appropriate), nitro, cyano, —COOR′, —OCOR′, NR′R″, linear or branched (C 1 -C 6 )polyhaloalkyl, trifluoromethoxy, (C 1 -C 6 )alkylsulphonyl, halogen, optionally substituted aryl, heteroaryl, aryloxy, arylthio, cycloalkyl, heterocycloalkyl optionally substituted by one or more halogen atoms or alkyl groups, wherein R′ and R″ independently of one another represent a hydrogen atom or an optionally substituted, linear or branched (C 1 -C 6 )alkyl group, wherein the Het group defined in formula (I) may be optionally substituted by from one to three groups selected from linear or branched (C 1 -C 6 )alkyl, hydroxy, linear or branched (C 1 -C 6 )alkoxy, NR 1 ′R 1 ″ and halogen, wherein R 1 ′ and R 1 ″ independently of one another represent a hydrogen atom or an optionally substituted, linear or branched (C 1 -C 6 )alkyl group, or an enantiomer, a diastereoisomer, or an addition salt thereof with a pharmaceutically acceptable acid or base.